Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Opens De-Regulation Docket To Collect Ideas For Repealing, Modifying Deficient Rules

This article was originally published in The Pink Sheet Daily

Executive Summary

House oversight committee hears plea for more transparent, predictable regulatory processes at FDA.
Advertisement

Related Content

Bar Code Rule Could Be Revised Under FDA Reg Review Initiative
Bar Code Rule Could Be Revised Under FDA Reg Review Initiative
PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA
PhRMA Seeks Repeal Of Brand Name Review Rule Until A Benefit Is Shown
FDA Gains No Impartiality Benefit From Conflict-Of-Interest Policy, Advocates Say
Berwick Wants To Simplify CMS Rules
Industry Skeptical Of User Fee Success, PricewaterhouseCoopers Finds
Industry Skeptical Of User Fee Success, PricewaterhouseCoopers Finds

Topics

Advertisement
UsernamePublicRestriction

Register

PS072153

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel